Chugai pulls out of Telomelysin deal with Oncolys

19 October 2021

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) today announced that the company and oncology specialist Oncolys BioPharma (TYO: 4588) have agreed to terminate the license agreement concluded between the two companies on April 8, 2019 for an oncolytic viral immunotherapy OBP-301 (Telomelysin: suratadenoturev).

The effective date of the termination will be decided upon consultation with Oncolys, at the latest by October 2022. Upon termination of the agreement, all rights Chugai may have with respect to OBP-301 will be returned to Oncolys. There will be no payment or receipt of milestone fees between the two companies. Chugai’s shares edged up 1.6% to 3,984 yen on the news, while those of Oncolys turned volatile, lurching between 1,139 and 1,157 yen but ended the day barely changed.

Reasons for the termination

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK